Innova Captab Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹6,014 Cr
- P/E
- 39.05
- ROE
- 13.69%
- PEG
- 1.36
- Price to sales
- 3.44
- Debt to equity
- 0.32
- 52W high / low
- ₹1,298 / ₹645
- Sales growth (5Y)
- 31.75%
- EBITDA margin
- 14.83%
- Net profit margin
- 8.61%
- Promoter holding
- 50.90%
- Sales (last year)
- ₹1,749 Cr
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
Guidance scorecard · Q1 FY27 call
What Innova Captab Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
20–40%- Innova Captab expects to deliver over 20% volume growth year-on-year, maintaining this growth trajectory in upcoming quarters.
- The guidance is approximately 20%+ volume growth for the full fiscal year FY27.
- Growth is driven by ramp-up at the Jammu plant, expanding product portfolio, onboarding new customers and geographies, and deeper engagement with existing customers.
- The Jammu facility, currently at 25-30% utilization, is projected to ramp up steadily, aiming to cross INR1,000 crores revenue.
- The company aims for 20%+ sales growth, combining volume growth and favorable pricing/product mix.
2 more points from Innova Captab Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
Up 0–2%See what Innova Captab Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
PlannedAsk what Innova Captab Ltd said on capex →
Full Q1 FY27 analysisFundraisingQ1 FY27 call
Ask what Innova Captab Ltd said on fundraising →
Full Q1 FY27 analysisOrder bookQ1 FY27 call
Rising- The management referred to healthy visibility of new products and geographies contributing to growth.
- Jammu plant ramp-up and onboarding of new customers, products, and country approvals are underway, implying a growing order pipeline.
- The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities.
2 more points from Innova Captab Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Innova Captab Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Innova Captab Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Innova Captab Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 241 | 233 | 283 | 302 | 263 | 294 | 318 | 316 | 315 | 352 | 380 | 450 | 448 |
| Expenses + | 214 | 202 | 242 | 258 | 225 | 252 | 268 | 270 | 267 | 299 | 329 | 381 | 383 |
| Operating Profit | 27 | 31 | 40 | 45 | 38 | 42 | 50 | 47 | 48 | 52 | 52 | 69 | 65 |
| OPM % | 11% | 13% | 14% | 15% | 14% | 14% | 16% | 15% | 15% | 15% | 14% | 15% | 15% |
| Other Income + | 3 | 1 | 3 | 2 | 6 | 2 | 2 | 4 | 3 | 4 | 4 | 2 | 2 |
| Interest | 5 | 5 | 9 | 7 | 1 | 0 | 0 | 0 | 2 | 3 | 6 | 4 | 5 |
| Depreciation | 3 | 3 | 5 | 5 | 3 | 5 | 5 | 5 | 10 | 11 | 11 | 11 | 11 |
| Profit before tax | 21 | 25 | 30 | 35 | 40 | 39 | 47 | 46 | 39 | 43 | 39 | 56 | 51 |
| Tax % | 19% | 28% | 24% | 29% | 27% | 25% | 25% | 25% | 25% | 27% | 24% | 24% | 25% |
| Net Profit + | 17 | 18 | 23 | 25 | 29 | 29 | 35 | 34 | 30 | 31 | 30 | 42 | 38 |
| EPS in Rs | 3.59 | 3.66 | 4.77 | 4.39 | 5.02 | 5.15 | 6.12 | 5.98 | 5.17 | 5.42 | 5.18 | 7.37 | 6.65 |
Financials of Innova Captab Ltd
Profit & Loss
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 356 | 373 | 411 | 801 | 926 | 1,081 | 1,244 | 1,630 |
| Expenses + | 315 | 322 | 356 | 704 | 813 | 927 | 1,057 | 1,387 |
| Operating Profit | 41 | 51 | 54 | 96 | 114 | 154 | 186 | 243 |
| OPM % | 11% | 14% | 13% | 12% | 12% | 14% | 15% | 15% |
| Other Income + | 0 | 1 | 1 | 3 | 9 | 12 | 12 | 7 |
| Interest | 6 | 5 | 4 | 6 | 20 | 21 | 2 | 17 |
| Depreciation | 11 | 10 | 6 | 8 | 11 | 16 | 25 | 45 |
| Profit before tax | 25 | 38 | 46 | 86 | 92 | 130 | 171 | 188 |
| Tax % | 20% | 26% | 26% | 25% | 26% | 27% | 25% | 25% |
| Net Profit + | 20 | 28 | 34 | 64 | 68 | 94 | 128 | 141 |
| EPS in Rs | 165.67 | 232.42 | 287.50 | 532.92 | 14.16 | 16.49 | 22.41 | 24.63 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Innova Captab Ltd
Balance Sheet
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 48 | 57 | 57 | 57 |
| Reserves | 70 | 98 | 133 | 197 | 229 | 774 | 902 | 1,034 |
| Borrowings + | 72 | 54 | 46 | 199 | 237 | 245 | 338 | 344 |
| Other Liabilities + | 68 | 81 | 179 | 167 | 191 | 240 | 271 | 403 |
| Total Liabilities | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,568 | 1,837 |
| Fixed Assets + | 78 | 73 | 79 | 183 | 183 | 358 | 830 | 842 |
| CWIP | 0 | 0 | 7 | 0 | 22 | 341 | 23 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 |
| Other Assets + | 144 | 172 | 283 | 392 | 500 | 617 | 716 | 939 |
| Total Assets | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,568 | 1,837 |
Financials of Innova Captab Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 19 | 31 | 42 | 59 | 67 | 146 | 64 | 117 |
| Cash from Investing Activity + | -9 | -6 | -20 | -188 | -91 | -499 | -152 | -107 |
| Cash from Financing Activity + | -9 | -23 | -19 | 125 | 27 | 361 | 92 | -22 |
| Net Cash Flow | 1 | 1 | 3 | -5 | 3 | 8 | 4 | -12 |
| Free Cash Flow | 11 | 27 | 23 | -21 | -11 | -141 | -108 | 55 |
| CFO/OP | 68% | 79% | 101% | 83% | 76% | 113% | 47% | 59% |
Financials of Innova Captab Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 85 | 123 | 97 | 104 | 97 | 97 | 98 |
| Inventory Days | 50 | 84 | 107 | 76 | 77 | 91 | 119 | 98 |
| Days Payable | 80 | 92 | 132 | 86 | 105 | 113 | 115 | 110 |
| Cash Conversion Cycle | 64 | 77 | 99 | 87 | 77 | 75 | 101 | 86 |
| Working Capital Days | 30 | 45 | 39 | 37 | 58 | 77 | 81 | 95 |
| ROCE % | 26% | 28% | 31% | 24% | 19% | 15% | 15% |
Guidance history
How Innova Captab Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 20–40% | Up 0–2% | Planned | — | Rising |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q3 FY26 call → | 20–40% | Flat | Planned | — | Rising |
| Q2 FY26 call → | 20–40% | Flat | Planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
80 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +28.8% | 77% |
| Last 6 months | +39.8% | 85% |
| Last 3 months | +8.4% | 77% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Innova Captab Ltd: 0.4 × 77 + 0.4 × 85 + 0.2 × 77 = 80.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Innova Captab Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY